Clinical trial
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle…
NCT00261612 · Medical University of Vienna, Other · Unknown status
Key facts
| NCT number | NCT00261612 |
|---|---|
| Title | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma |
| Lead sponsor | Medical University of Vienna, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Mantle-Cell |
| Intervention type | Drug, Procedure |
| Interventions | bortezomib, rituximab, dexamethasone, treatment protocol |
| Enrollment | 16 |
| Start date | Jan 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Dec 5, 2005 |
| Last update posted | Oct 18, 2006 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: